ZYDELIG® for relapsed FL
after ≥2 systemic therapies

ZYDELIG achieved 54% ORR in a pivotal phase 2 open-label trial (95% CI, 42%-66%) 8% CR, 46% PR; n=72

Accelerated approval was granted for FL based on overall response rate. An improvement in patient survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification of clinical benefit in confirmatory trials.

ZYDELIG is not indicated or recommended for first-line treatment of any patient.

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) RECOMMEND IDELALISIB
for appropriate patients with relapsed/refractory FL.1*

*Please see the complete version of the NCCN Guidelines® for Non-Hodgkin’s Lymphomas available on NCCN.org for specific recommendations.

CI=confidence interval; CR=complete response; FL=follicular B-cell non-Hodgkin lymphoma; NCCN®=National Comprehensive Cancer Network®; ORR=overall response rate;
PR=partial response.